Eplerenone GD Searle & Co

Current Opinion in Investigational Drugs

Volumn 2, Issue 4, 2001, Pages 521-524

  Martin, J ^a   Krum, H ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; BRAIN NATRIURETIC PEPTIDE; CORTICOSTEROID ANTAGONIST; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; OXYGENASE; PLACEBO; RENIN; SODIUM; SPIRONOLACTONE;

AREA UNDER THE CURVE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; GYNECOMASTIA; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY DISEASE; NONHUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STRUCTURE ACTIVITY RELATION;

ALDOSTERONE ANTAGONISTS; ANIMALS; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; KIDNEY DISEASES; SPIRONOLACTONE;

EID: 0035050145     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Antialdosterones: Incidence and prevention of sexual side effects
2. Searle healthnet: Products in development
3. Monsanto reports 1998 fourth-quarter and full-year results
4. Searle's investigational agent Eplerenone being studied in large, global cardiovascular survival trial
5. The effects of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators
6. Product Pipeline - 1998 annual report - Investor relations - Monsanto
7. Drug development pipeline
8. Mineralocorticoid receptor antagonists: The evolution of utility and pharmacology
9. Eplerenone studied in global cardiovascular survival trial
10. Eplerenone, a new mineralocorticoid antagonist: In vitro and in vivo studies
11. Adrenal cortex
12. Aldosterone antagonists in hypertension and heart failure
13. Selective aldosterone receptor antagonism attenuates ventricular dilatation and reactive fibrosis but does not affect wound healing following myocardial infarction
14. Eplerenone. Antihypertensive, treatment of heart failure, aldosterone antagonist
15. Eplerenone, a novel selective aldosterone receptor antagonist (SARA): Dose finding study in patients with heart failure
16. Mineralocorticoid receptor blockade in the remnant kidney model
17. Aldosterone and cardiac hypertrophy: Effects of eplerenone on LV function and hypertrophic remodeling in LV pressure overload
18. Role of mineralocorticoids in renal injury in stroke-prone hypertensive rats
19. Eplerenone, a new selective aldosterone receptor antagonist (SARA): Efficacy in patients with mild to moderate hypertension
20. Mineralcorticoid blockade reduces vascular injury in strokeprone hypertensive rats
21. Steroidal, aldosterone antagonists: Increased selectivity of 9α, 11-epoxy derivatives
22. Three new epoxy-spironolactone derivatives: Characterisation in vivo and in vitro
23. Eplerenone, a selective antagonist of the aldosterone receptor
24. Eplerenone (SC 66110), a highly selective aldosterone antagonist
25. Effects of the selective mineralcorticoid receptor antagonist, eplerenone, in a model of aldosterone-induced hypertension and cardiac fibrosis
26. Eplerenone, a novel and selective aldosterone receptor antagonist: Efficacy in patients with mild to moderate hypertension
27. Aiming to rank 20th within this year: Mr Payne of Pharmacia